Dermira (NASDAQ:DERM) Stock Upgrade
Citigroup upgraded the shares of Dermira (NASDAQ:DERM) from a Neutral rating to Buy rating in analysts note disseminated on Friday morning.
From a total of 5 analysts covering Dermira Inc (NASDAQ:DERM) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $42 while the lowest target price is $33. The mean of all analyst targets is $38.8 with a 10.59% above today’s ($34.36) stock price. Dermira Inc was the topic of 4 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Cowen & Co initiated shares on August 19 with “Outperform” rating.
Approximately 144,354 shares of stock traded hands. Dermira Inc (NASDAQ:DERM) has risen 121.64% since May 15, 2015 and is uptrending. It has outperformed by 125.45% the S&P500.
The overall sentiment of institutions has increased to 3.59 in Q2 2015. Its up 0.72, from 2.87 in 2015Q2. The ratio improved, as 7 institutions have sold all the shares of Dermira Inc that they owned while 10 funds have taken shares off the table. 21 funds have purchased shares for the first time while 40 added to their positions. These institutions now hold 49.29 million shares or 237.01% more than the 14.62 million shares they owned in 2015Q2.
The Fund New Leaf Venture Partners L.L.C. currently is holding shares equating to 5.7% of its total portfolio in Dermira Inc representing a total of 281,592 shares. Another fund,Nea Management Company Llc, is holding a total of 3.51 million shares equating to 5.39% of their holdings. Additionally, Aisling Capital Llc has a 1.10 million share stake in Dermira Inc which represents 4.52% of their total portfolio. The Fund, Venbio Select Advisor Llc, based out of California, has also built up a stake in the stock, which represents a total of 2.2% of their total portfolio. Finally Abingworth Llp, a fund which is based in the state of United Kingdom reported a total holdings of 70,000 shares.
Insider activity is a very important aspect to track on any stock. Going back to September 15, 2015, shareholders of Dermira Inc have witnessed 0 insider purchases, and a total of 2 sales equating to a net activity of approximately $688,410 . Bauer Eugene A sold 2,500 shares worth approximately $57,174.
Dermira, Inc. is a specialty biopharmaceutical firm focused on bringing medical dermatology products to dermatologists and their patients. The company has a market cap of $1.01 billion. The Company’s portfolio of five product candidates includes three late-stage product candidates. It currently has negative earnings. The late-stage product candidates are Cimzia , which the Company is developing in collaboration with UCB Pharma S.A. (UCB), DRM04 and DRM01.
According to Zacks Investment Research, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California.”